Study identifies drivers of recurrent arthritis after immunotherapy, pointing to potential biomarkers

A new study from The University of Texas MD Anderson Cancer Center suggests that inflammatory arthritis triggered by immune checkpoint inhibitors may behave less like a series of unrelated complications and more like an immune-memory disease. The findings, published in Cancer Immunology Research, identify immune cell populations that reappeared during both patients’ initial and recurrent arthritis flares. Their return was accompanied by stronger inflammatory activity, offering a possible explanation for why later episodes can become more severe and persistent.

Immune checkpoint inhibitors have transformed cancer treatment by releasing molecular “brakes” that normally restrain T cells. Drugs targeting pathways such as PD-1, PD-L1 and CTLA-4 can therefore enhance the immune system’s ability to recognize and destroy tumor cells. However, the same amplified immune response can sometimes damage healthy tissues. When immune cells attack the joints, patients may develop immune checkpoint inhibitor-mediated inflammatory arthritis, a painful condition that can include swelling, stiffness and reduced mobility.

The complication is not necessarily limited to the period when patients are receiving treatment. According to the researchers, approximately 20% to 50% of affected patients experience arthritis more than once, while some continue to have symptoms for months or years after immunotherapy ends. Recurrent flares can be particularly disruptive, and clinical observations indicate that they are often more intense than the initial episode. Until now, it has remained unclear whether each flare represents a new inflammatory event or the reactivation of immune cells established during the first attack.

To investigate that question, researchers analyzed joint fluid collected from six patients during an initial arthritis flare and a subsequent recurrence. Joint fluid provides a direct view of the immune environment inside inflamed tissue, allowing scientists to examine the cells and signaling molecules active at the site of disease. Using immune profiling and molecular analyses, the team found two prominent immune cell populations in both episodes: inflammatory CD8 T cells and a specialized subset of CD4 T cells that simultaneously expressed PD-1 and CXCL13.

CD8 T cells are typically associated with the direct destruction of infected or abnormal cells, but in inflammatory arthritis they can also contribute to tissue damage by releasing cytokines and other immune mediators. PD-1 and CXCL13 co-expressing CD4 T cells represent a more specialized population involved in organizing immune reactions. PD-1 is a receptor associated with T-cell activation and regulation, while CXCL13 is a chemokine that helps attract and position immune cells within organized inflammatory niches. Their persistence across separate flares suggests that the joint may retain, or repeatedly recruit, a disease-associated immune network.

The researchers also found that these immune populations appeared to become more aggressive during recurrent disease. Cells present in the second flare produced higher levels of inflammatory signaling molecules, indicating that they were not merely surviving in the tissue but returning in a more activated state. This pattern resembles immunological memory, in which previously stimulated immune cells respond more rapidly and forcefully when they encounter a familiar signal. In this case, the response is directed toward joint-associated inflammation rather than a tumor or infectious pathogen.

An unexpected finding involved regulatory T cells, or Tregs. These cells ordinarily help prevent excessive immune activation and maintain tolerance to the body’s own tissues. During recurrent arthritis flares, however, Tregs also produced inflammatory molecules. The observation raises the possibility that regulatory cells may lose some of their protective function or become functionally altered within the highly inflammatory environment created by checkpoint inhibitor therapy. If confirmed in larger studies, this change could help explain why the body’s normal mechanisms for limiting joint inflammation fail during repeated episodes.

The study further revealed extensive communication networks among immune cells in the affected joints. These networks were characterized by signaling molecules that coordinate cell recruitment, activation and persistence. During the second flare, the connections became more pronounced, suggesting that recurrent arthritis is driven by a coordinated inflammatory ecosystem rather than by a small number of isolated cell types. Such molecular interactions may amplify inflammation over time and could provide multiple points for therapeutic intervention.

The findings may eventually help clinicians identify patients at high risk of recurrent arthritis before severe flares develop. The presence or activity of inflammatory CD8 T cells and PD-1-positive, CXCL13-producing CD4 T cells could potentially serve as biomarkers, although the results must be validated in larger patient groups. Researchers also hope to develop treatments that selectively interrupt the pathways responsible for joint inflammation without weakening the anti-cancer immune response. That balance is crucial: broadly suppressing immunity could reduce arthritis but might also compromise the ability of checkpoint inhibitors to control cancer.

Roza I. Nurieva, Ph.D., who co-led the study with Synat Keam, Ph.D., Yuanteng Jeff Li, M.D., and Sang Taek Kim, M.D., Ph.D., said that the persistence of anti-tumor immunity may have an unintended counterpart in recurring inflammatory disease. By defining the cells and molecular signals associated with repeated arthritis flares, the researchers have provided a framework for understanding this challenging side effect as an immune-memory process. Future work will determine whether these cellular signatures can predict recurrence and whether targeted therapies can protect patients’ joints while preserving the life-extending benefits of cancer immunotherapy.

News Publication Date: August 11, 2026

Web References: The University of Texas MD Anderson Cancer Center; Cancer Immunology Research; https://aacrjournals.org/cancerimmunolres/article/doi/10.1158/2326-6066.CIR-25-1639/787231/Immune-hallmarks-of-recurrent-immune-checkpoint

References: DOI: 10.1158/2326-6066.CIR-25-1639